173
Views
0
CrossRef citations to date
0
Altmetric
Original Article: Research

Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 2042-2049 | Received 23 Apr 2018, Accepted 25 Nov 2018, Published online: 22 Jan 2019

References

  • Blau O, Baldus CD, Hofmann WK, et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood. 2011;118:5583–5592.
  • Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–317.
  • Lee CCI, Christensen JE, Yoder MC, et al. Clonal analysis and hierarchy of human bone marrow mesenchymal stem and progenitor cells. Exp Hematol. 2010;38:46–54.
  • Bigildeev AE, Zhironkina OA, Shipounova IN, et al. Clonal composition of human multipotent mesenchymal stromal cells. Exp Hematol. 2012;40:847–856.e4.
  • Chen Q, Yuan Y, Chen T. Morphology, differentiation and adhesion molecule expression changes of bone marrow mesenchymal stem cells from acute myeloid leukemia patients. Mol Med Rep. 2014;9:293–298.
  • Zhao ZG, Liang Y, Li K, et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev. 2007;16:637–648.
  • Yin WJ, Yang PD, Huang YZ, et al. [Comparison of biological characteristics of bone marrow mesenchymal stem cells in acute myeloid leukemia with those from non-leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:395–399.
  • Zhao ZG, Xu W, Sun L, et al. The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia. Eur J Cancer. 2012;48:1884–1895.
  • Zhu GR, Zhou XY, Lu H, et al. [Human bone marrow mesenchymal stem cells express multiple hematopoietic growth factors]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11:115–119.
  • Zhao ZG, Sun L, Wang XF, et al. Immunomodulatory effects of mesenchymal stem cells derived from the bone marrow in acute leukemia patients. Chin J Oncol. 2011;33:105–109.
  • Parovichnikova EN, Troitskaia VV, Kliasova GA, et al. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center’s results]. Ter Arkh. 2014;86:14–23.
  • Lange C, Cakiroglu F, Spiess A, et al. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol. 2007;8904:18–26.
  • Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-a phase II study. Stem Cells Int. 2012;2012:1.
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.
  • Bigildeev AE, Zezina EA, Drize NJ. [The effects of interleukin-1 beta and gamma-quantum braking radiation on mesenchymal progenitor cells]. Mol Biol (Mosk). 2017;51:447–459.
  • Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–1108.
  • Spitzer M, Wildenhain J, Rappsilber J, et al. BoxPlotR: a web tool for generation of box plots. Nat Methods. 2014;11:121–122.
  • Desbourdes L, Javary J, Charbonnier T, et al. Alteration analysis of bone marrow mesenchymal stromal cells from de novo acute myeloid leukemia patients at diagnosis. Stem Cells Dev. 2017;26:709–722.
  • Shipounova IN, Petinati NA, Bigildeev AE, et al. Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2016;58:1–10.
  • Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150–1157.
  • Frisch BJ, Ashton JM, Xing L, et al. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 2012;119:540–550.
  • Kim JA, Shim JS, Lee GY, et al. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res. 2015;75:2222–2231.
  • Woods A, Brull DJ, Humphries SE, et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21:1574–1583.
  • Shellard J, Perreau J, Brûlet P. Role of leukemia inhibitory factor during mammalian development. Eur Cytokine Netw. 1996;7:699–712.
  • Trouillas M, Saucourt C, Guillotin B, et al. The LIF cytokine: towards adulthood. Eur Cytokine Netw. 2009;20:51–62.
  • Wetzler M, Talpaz M, Lowe DG, et al. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol. 1991;19:347–351.
  • Lopes MR, Pereira JKN, de Melo Campos P, et al. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Sci Rep. 2017;7:40707.
  • Hacia JG, Lee CCI, Jimenez DF, et al. Age-related gene expression profiles of rhesus monkey bone marrow-derived mesenchymal stem cells. J Cell Biochem. 2008;103:1198–1210.
  • Jiang Y, Mishima H, Sakai S, et al. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders. J Orthop Res. 2008;26:910–917.
  • Kiersnowska-Rogowska B, Rogowski F, Petelski T, et al. [Cytokines in acute myeloid leukemia]. Pol Merkur Lekarski. 1998;4:259–261.
  • Xiao R, Chen T, Zhou M, et al. [Abnormal expression of hematopoietic regulatory factors in newly diagnosed patients with acute myeloid leukemia]. Zhongguo Shi Yan Xue ye Xue za Zhi. 2010;18:1124–1127.
  • Ng F, Boucher S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and o. Blood. 2008;112:295–307.
  • Hu WL, Wu PP, Yin CC, et al. [Effects of leukemia inhibitory factor combined with basic fibroblast growth factor on self-maintenance and self-renewal of human umbilical cord mesenchymal stem cells in vitro]. Zhongguo Shi Yan Xue ye Xue za Zhi. 2016;24:184–190.
  • Horacek JM, Kupsa T, Vasatova M, et al. Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia. Exp Oncol. 2014;36:50–51.
  • Zhang W, Qiao Z, Fan X, et al. [The role of intercellular adhesion molecule-1 in binding of acute myeloid leukemic blasts cells to human umbilical vein endothelial cells]. Zhonghua Nei ke za Zhi. 2003;42:413–416.
  • Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. 2010;184:2321–2328.
  • Kampen KR, Ter Elst A, de Bont ES. Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci. 2013;70:1307–1317.
  • Sanaat Z, Khalili R, Almasi S, et al. Does chemotherapy change expression of VEGF A&C and MVD in acute myeloid leukemia? Int J Hematol Oncol Stem Cell Res. 2014;8:24–29.
  • Mikkola HK, Orkin SH. The journey of developing hematopoietic stem cells. Development. 2006;133:3733–3744.
  • Fouillard L, Francois S, Bouchet S, et al. Innovative cell therapy in the treatment of serious adverse events related to both chemo-radiotherapy protocol and acute myeloid leukemia syndrome: the infusion of mesenchymal stem cells post-treatment reduces hematopoietic toxicity and promotes hematopoietic reconstituion. Curr Pharm Biotechnol. 2014;14:842–848.
  • Voermans C, van Heese WPM, de Jong I, et al. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia. 2002;16:650–657.
  • Juarez J, Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol. 2004;19:299–309.
  • Liao J, Hu N, Zhou N, et al. Sox9 potentiates BMP2-induced chondrogenic differentiation and inhibits BMP2-induced osteogenic differentiation. PLoS One. 2014;9:e89025. Shi X-M, editor.
  • Loebel C, Czekanska EM, Bruderer M, et al. In vitro osteogenic potential of human mesenchymal stem cells is predicted by Runx2/Sox9 ratio. Tissue Eng Part A. 2015;21:115–123.
  • Shipounova IN, Petinati NA, Bigildeev AE, et al. Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2017;58:408–417.
  • Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014;123:3574–3577.
  • Kim HG, Jang JH, Koh EH. TRIP11-PDGFRB fusion in a patient with a therapy-related myeloid neoplasm with t(5;14)(q33;q32) after treatment for acute promyelocytic leukemia. Mol Cytogenet. 2014;7:103.
  • Vega F, Medeiros LJ, Bueso-Ramos CE, et al. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144:377–392.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.